{
    "Trade/Device Name(s)": [
        "BOND MMR Antibody Panel",
        "Leica Biosystems BOND MMR Antibody Panel",
        "Lynch Syndrome Test System"
    ],
    "Submitter Information": "Leica Biosystems Newcastle Ltd.",
    "510(k) Number": "K213348",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170030"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZJ"
    ],
    "Summary Letter Date": "November 10, 2022",
    "Summary Letter Received Date": "November 23, 2022",
    "Submission Date": "September 30, 2021",
    "Regulation Number(s)": [
        "21 CFR 864.1866"
    ],
    "Regulation Name(s)": [
        "Lynch Syndrome Test Systems"
    ],
    "Analyte Class(es)": [
        "anatomic pathology",
        "cancer molecular",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "MLH1",
        "MSH2",
        "MSH6",
        "PMS2"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissue sections"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BOND-III",
        "BOND-MAX"
    ],
    "Method(s)/Technology(ies)": [
        "Immunohistochemistry (IHC) staining",
        "Polymer Refine Detection",
        "Light microscopy"
    ],
    "Methodologies": [
        "Protein expression profiling",
        "Immunohistochemical staining"
    ],
    "Submission Type(s)": [
        "Panel",
        "Reagent",
        "Antibody",
        "Kit",
        "System",
        "Automated system",
        "Detection system"
    ],
    "Document Summary": "FDA 510(k) summary for Leica Biosystems BOND MMR Antibody Panel, an IHC panel for the qualitative identification of MMR proteins MLH1, MSH2, MSH6, and PMS2 in FFPE colorectal cancer tissues to aid identification of Lynch syndrome using BOND-III/BOND-MAX automated platforms.",
    "Indications for Use Summary": "Qualitative identification of human mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2 in FFPE colorectal cancer tissue sections by immunohistochemistry, as an aid in identifying potential hereditary nonpolyposis colorectal cancer (Lynch syndrome) in CRC-diagnosed patients; not for CRC diagnosis or use in other indications.",
    "fda_folder": "Immunology"
}